Michèle Bartlett is a psychotherapist and writer. Diagnosed with Parkinson’s disease six years ago, she has been an active contributor to a broad range of research initiatives. Drawing on her experiences of participating in a number of clinical trials and studies, she is a passionate advocate for integrating patient perspectives into research at all levels. She is Deputy Chair of the PPIE working group for the EJS ACT-PD initiative: developing the first multi-arm, multi-stage trial for potential disease modifying treatments for Parkinson’s disease in the UK. She is Co-Chair on behalf of PwP on the Critical Path for Parkinson’s Advisory Council for Patient-Centric Endpoints.

Faisal M. Khan, PhD is the Corporate Vice President for Artificial Intelligence and Analytics at Novo Nordisk. His team focuses on the applications of AI and data science throughout the drug development lifecycle. His interests focus on the intersections of data science, digital health, biostatistics, bioimaging, personalized medicine, and healthcare delivery. His career has encompassed all aspects of healthcare and biomedical analytics, including diagnostics, devices, clinical trials/therapeutics, and payers/insurance. Dr Khan has worked or consulted across academia and industry with both startups and Fortune-50 companies. He has over 100 published papers, abstracts, and patents on the applications of machine learning and artificial intelligence for healthcare and the life sciences.

Madelaine MacKay has 20 Years experience in the clinical research industry with a background in global project management and clinical management. For the past 8 years her focus has been on strategic implementation and operationalization of technology that incorporates research activities into the patient’s lifestyle. Currently at ICON, Ms MacKay is the head of the Platform Solution Enablement team within eClinical Development and Delivery that helps sites connect with their patients for modern clinical trials.

Ian Thompson has been with Ypsomed AG, formerly Disetronic AG, since 1995 in a number of roles in key account management and business development working with pharma companies to develop and bring to market innovative self-injection systems. He studied biochemistry and biotechnology in the UK from 1979-1983 and has worked in medical device companies since moving to Switzerland in 1990. Since 2003 his main focus has been business development and new product innovation for Ypsomed Delivery Systems Platform Products: pen, autoinjector, wearable and connected injector technologies.

Jodie Huddleston is the Senior Managing Director and Head of Clinical Solutions for Life Sciences at Press Ganey with 30 years of experience leading clinical trial operations in the CRO, academic medical, community hospital, and vendor support services spaces. Over the past ten years, Jodie has been primarily focused on strategy and operations for decentralized clinical trial solutions with a focus on patient-centric innovation and direct-to-patient services.  Jodie has extensive experience in building and growing innovative offerings and disruptive models in Life Sciences. Prior to joining Press Ganey, she held leadership roles at Worldwide Clinical Trials, ICON, IQVIA, Lightship and CVS Health. Earlier in her career, Jodie worked in academia leading clinical trial operations at University Hospitals of Cleveland, Case Western Reserve University and Children’s Hospital in Colorado. She also built out a new Site Network model for the Center for Clinical Trials at Catholic Health Initiatives where she served as National Director.  Additionally, Jodie was Principal of her own consulting firm for many years and was contracted by several well-known start-up companies to assist them in building and implementation of innovative clinical trial solutions.

Deirdre Bevard brings over three decades of expertise in the pharmaceutical industry and is known for authentic and transformative leadership. As the Senior Vice President of R&D Strategic Operations at CSL, she oversees a global team focused on portfolio management, clinical operations delivery, integrated business operations, digital strategies, and patient-centered drug development. Ms Bevard’s leadership philosophy emphasizes collaboration, integrity, and innovation, creating inclusive environments where teams thrive and deliver impactful results. Her diverse experience spans key roles at Elligo Health Research, Nektar Therapeutics, and Endo Pharmaceuticals, as well as a CRO and a start-up software company. This broad perspective gives her a diverse perspective and fuels her passion for bridging clinical research and healthcare through partnering with patients, communities, and providers to accelerate medical advancements and enhance health equity. Ms Bevard is committed to making a lasting impact on the industry. She thrives in strategic and collaborative environments, and is frequently sought for her vision, insights, and enterprise connectivity. Beyond her professional achievements, Ms Bevard enjoys family time, good books, a well-crafted cocktail, and a good laugh. Her leadership style reflects her mindset to take her work seriously, but maintain a lighthearted approach about herself, embracing humility.

Terttu Haring, MD, is a Clinical Operations Executive with a strong focus on Investigators, Sites and Patients. She received her MD from Maastricht University in the Netherlands. 

Over her nearly 30 years in the industry, she has seen clinical trials from different angles in research sites, in large pharma and in CRO setting. Roles she has had include investigator and research director; management of local and regional clin ops teams in Netherlands, Europe & Africa; leadership of global trial operations and data management activities and pushing digital innovations to clinical operations.

Development of new treatment options needs patients to enroll in clinical trials. It is Terttu’s mission to bring trials to patients around the world, setting investigators up for successful and effective trial execution so we bring treatments for life with less symptoms and more years to the market faster.